On November 11, 2026 Hangzhou Eli Radiopharma Co., Ltd. ("Eli Radiopharma", or "the Company"), an innovative radiopharmaceutical company focused on integrated diagnostics and therapeutics for oncology and neurological diseases, reported the completion of a Series A financing round of nearly RMB 400 million. The round was led by Huagai Capital, with Bayland Capital as co-lead investor, and participation from Boyu Ventures, Delian Capital, InnoPinnacle Fund, Haibang Venture, Bairui Capital, Shenzhen Angel FOF Management, and Grand Flight Investment. Existing shareholders CSPC & Growth Bio Fund, Huaige Capital, KHK Fund, Longfeng Venture, Hongsheng Capital, Bioclub Fund, and Skyfield Capital also participated in the round.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The proceeds will primarily support the advancement of the Company’s core innovative pipeline toward clinical development. Funding will be directed toward preclinical research, clinical trial applications, and early-stage clinical development, alongside further investment in R&D platforms, talent acquisition, and the Company’s clinical and business development. The financing will provide strong support for the continued advancement of the Company’s pipeline and its long-term growth. To date, the Company has advanced multiple programs targeting novel molecular targets through lead discovery and in vitro and in vivo validation, with promising target specificity and drug development potential. Several programs are approaching IND submission.
"The completion of this financing round marks an important milestone in Eli Radiopharma’s development and reflects our investors’ confidence in our R&D strategy, technological capabilities, and long-term vision," stated Dr. Feng Yu, Founder and CEO of Eli Radiopharma. "Moving our pipeline toward the clinic is a critical next step in translating our research into meaningful advances for patients. This financing will support our efforts to advance our lead programs through preclinical development and regulatory milestones, bringing differentiated radiopharmaceutical candidates closer to clinical evaluation. We remain focused on addressing unmet clinical needs and strengthening our R&D and clinical development capabilities, with the goal of delivering precision diagnostic and therapeutic options for patients with cancer and neurological diseases."
Cynix Wang, Chief Investment Officer of Healthcare at Huagai Capital, said, "Radiopharmaceuticals represent an exciting area of innovation at the intersection of molecular targeting, radionuclide technology, and precision theranostics. As the field continues to advance, expanding clinical applications, progress in therapeutic radionuclides, and the development of novel targets and differentiated pipelines are creating new opportunities for the radiopharmaceutical industry. The two BD deals in 2026 involving multinational pharmaceutical companies and Chinese radiopharmaceutical innovators further underscore the growing global recognition of China’s innovation capabilities and the significant potential for international partnerships. We are encouraged by Eli Radiopharma’s focused approach to radiopharmaceutical R&D and its ability to advance novel candidates into clinical development. Our investment reflects our confidence in the Company’s scientific capabilities and long-term potential. We look forward to supporting the advancement of its pipeline and helping translate promising science into clinical applications, while contributing to the broader advancement of the radiopharmaceutical field."
Xi Zou, Director and Project Lead at Bayland Capital, commented: "Bayland Capital has long been closely following innovations in the global radiopharmaceutical sector and strongly recognizes the clinical value and growth potential of radioligand therapy (RLT). We believe that, as more innovative therapies gain regulatory approval, RLT will play an increasingly important role in the treatment of a broad range of solid tumors. Eli Radiopharma has demonstrated distinct competitive strengths in its R&D strategy, innovation capabilities, and development efficiency. The company continues to expand its team, strengthen its technology and development capabilities, and steadily advance its global strategy. We are confident in Eli Radiopharma’s potential to build a globally competitive pipeline of innovative radiopharmaceuticals and deliver meaningful clinical value in international markets, including the US and Europe. Bayland Capital is delighted to co-lead this financing round. Looking ahead, we will continue to support Eli Radiopharma in expanding its technology platforms, accelerating the clinical development of its lead programs, and advancing differentiated, globally competitive radiopharmaceuticals, helping bring China-originated innovation to patients worldwide."
Yilun LIU, Partner of Boyu Ventures, said, "Radiopharmaceuticals hold significant potential to advance precision diagnostics and therapeutics. Eli Radiopharma is building a differentiated pipeline targeting oncology and neurological diseases with a clear focus on addressing unmet clinical needs. We believe the Company’s scientific expertise and R&D capabilities provide a strong foundation for advancing its pipeline toward clinical development. We look forward to seeing Eli Radiopharma progress its innovative programs and translate its research into meaningful clinical value for patients."
(Press release, Hangzhou Eli Radiopharma, NOV 11, 2026, View Source [SID1234674633])